MoonLake Immunotherapeutics’s filing revealed that its Chief Executive Officer Santos da Silva Jorge unloaded Company’s shares for reported $0.26 million on Feb 29 ’24. In the deal valued at $55.89 per share,4,740 shares were sold. As a result of this transaction, Santos da Silva Jorge now holds 2,982,814 shares worth roughly $140.7 million.
Then, Santos da Silva Jorge sold 56,065 shares, generating $3,083,575 in total proceeds. Upon selling the shares at $55.00, the Chief Executive Officer now owns 2,987,554 shares.
Before that, Reich Kristian sold 31,910 shares. MoonLake Immunotherapeutics shares valued at $1,755,050 were divested by the Chief Scientific Officer at a price of $55.00 per share. As a result of the transaction, Reich Kristian now holds 2,925,573 shares, worth roughly $138.0 million.
Goldman initiated its MoonLake Immunotherapeutics [MLTX] rating to a Neutral in a research note published on April 02, 2024; the price target was $62. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Citigroup began covering MLTX with “Buy” recommendation on December 08, 2023. Stifel started covering the stock on November 02, 2023. It rated MLTX as “a Buy”.
Price Performance Review of MLTX
On Friday, MoonLake Immunotherapeutics [NASDAQ:MLTX] saw its stock jump 2.57% to $47.17. Over the last five days, the stock has lost -6.09%. MoonLake Immunotherapeutics shares have fallen nearly -21.89% since the year began. Nevertheless, the stocks have risen 148.13% over the past one year. While a 52-week high of $64.98 was reached on 02/12/24, a 52-week low of $17.82 was recorded on 03/14/24. SMA at 50 days reached $52.73, while 200 days put it at $53.00. A total of 0.58 million shares were traded, compared to the trading of 0.38 million shares in the previous session.
Levels Of Support And Resistance For MLTX Stock
The 24-hour chart illustrates a support level at 46.01, which if violated will result in even more drops to 44.84. On the upside, there is a resistance level at 48.02. A further resistance level may holdings at 48.86. The Relative Strength Index (RSI) on the 14-day chart is 42.85, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.17%. Stochastics %K at 25.02% indicates the stock is a holding.
How much short interest is there in MoonLake Immunotherapeutics?
A steep rise in short interest was recorded in MoonLake Immunotherapeutics stocks on Mar 15, 2024, growing by 0.39 million shares to a total of 7.0 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 6.61 million shares. There was a rise of 5.57%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 20.45% of the overall stock float, the days-to-cover ratio (short ratio) rose to 11.15.
